MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Post-traumatic stress disorder (PTSD) is a disabling condition with substantial individual and societal burden; many patients have persistent symptoms and poor responses to existing treatments, including selective serotonin reuptake inhibitors (SSRIs). Earlier trials and mechanistic work suggested that 3,4-methylenedioxy­methamphetamine-assisted therapy (MDMA-AT) may enhance psychotherapeutic engagement and facilitate fear extinction and memory reconsolidation, but confirmatory data in a diverse sample with moderate to severe PTSD were limited. Mitchell and colleagues conducted MAPP2, a multi-site, randomized, double-blind, placebo-controlled Phase III trial, to test whether MDMA-AT reduces clinician-rated PTSD symptom severity and improves functional impairment compared with placebo plus identical therapy. The trial aimed to extend findings from an earlier Phase III study (MAPP1) into an ethnoracially diverse population with longstanding moderate to severe PTSD and several comorbidities.

This was a multi-site, randomized, double-blind, placebo-controlled Phase III trial (ClinicalTrials.gov: NCT04077437) conducted at 13 sites (11 US, two Israel). Adults aged 18 and over who met DSM-5 criteria for current PTSD on the CAPS-5, with a CAPS-5 total severity score ≥28 and symptoms for at least 6 months, were eligible after informed consent. During a preparation period participants were tapered off psychiatric medications before baseline; full inclusion and exclusion criteria were reported in the Supplementary Methods (not fully reproduced in the extracted text). Thirteen participants sites enrolled participants between August 2020 and May 2022. Participants were randomised 1:1 to MDMA-assisted therapy (MDMA-AT) or placebo with identical therapy, stratified by site using an interactive web randomisation system. Blinded independent assessors, centrally trained and supervised to ensure inter-rater reliability, performed outcome assessments; assessors were blinded to treatment assignment and study details to reduce functional unblinding. A blinding survey was administered at study end to assess perceived assignment. The intervention comprised three 90-minute preparation sessions followed by three 8-hour experimental dosing sessions approximately one month apart, each followed by three 90-minute integration sessions. Therapy teams of two, including at least one licensed therapist, delivered the MAPS MDMA-AT manualised psychotherapy. MDMA was administered as split doses: session 1 used 80 mg + 40 mg (total 120 mg) and sessions 2 and 3 used 120 mg + 60 mg (total 180 mg), with the supplemental half dose given 1.5–2 hours after the initial dose. Participants in both arms received identical psychotherapy and the same visit schedule. Primary and key secondary outcomes were mean change from baseline to 18 weeks on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the Sheehan Disability Scale (SDS), respectively; independent assessors conducted these measures via video interviews at baseline, after experimental sessions 1 and 2, and 6–8 weeks after experimental session 3 (week 18). Responder definitions included a ≥10-point CAPS-5 reduction as clinically meaningful; categorical outcomes included responder, loss of diagnosis, and remission (CAPS-5 ≤11 and no longer meeting PTSD diagnostic criteria). Safety assessments tracked treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest (TEAESIs) including cardiac events, suicidality, and MDMA misuse, and vital signs. Suicidality was measured via the Columbia-Suicide Severity Rating Scale (C-SSRS). Efficacy analyses used mixed models for repeated measures (MMRM) comparing change from baseline to week 18, with fixed effects for treatment, visit, treatment-by-visit interaction and dissociative subtype, and baseline CAPS-5 as a covariate. Two estimands were prespecified: a de jure (reflecting initially randomised treatment) primary estimand and a supportive de facto estimand; the modified intention-to-treat population required exposure to study drug and at least one follow-up CAPS-5. Sample size was powered at 90% with alpha set at 0.0499 (adjusted for an interim sample size re-estimation). Additional exploratory covariate analyses assessed up to 13 factors including age, sex, prior SSRI use, disease severity, dissociative subtype and baseline depression. Missing data were treated as missing at random and assessed with sensitivity (tipping point) analyses.

Of 324 screened, 121 consented and entered preparation; 104 participants were confirmed and randomised (53 to MDMA-AT, 51 to placebo with therapy). Ninety-four participants completed the study; nine discontinued (one in MDMA-AT; eight in placebo). The sample was majority assigned female at birth (74/104, 71.2%), ethnoracially diverse (35/104, 33.7% identified race other than White; 28/104, 26.9% identified as Hispanic/Latino) with a mean PTSD duration of 16.2 (s.d. 13.3) years and a baseline mean CAPS-5 score of 39.0 (s.d. 6.6). Overall, 26.9% had moderate PTSD and 73.1% had severe PTSD; 23.1% met criteria for the dissociative subtype. Primary outcome: MMRM analysis of the de jure estimand showed greater reduction in CAPS-5 total severity with MDMA-AT versus placebo with therapy at 18 weeks. The least-squares (LS) mean change was −23.7 (95% CI −26.94, −20.44) for MDMA-AT versus −14.8 (95% CI −18.28, −11.28) for placebo with therapy, giving a treatment difference of −8.9 (95% CI −13.70, −4.12), P < 0.001. The between-group Cohen's d was 0.7; within-group effect sizes were d = 1.95 for MDMA-AT and d = 1.25 for placebo with therapy. Supportive de facto analyses produced consistent results. Key secondary outcome: Functional impairment measured by SDS improved more with MDMA-AT. LS mean change was −3.3 (95% CI −4.03, −2.60) for MDMA-AT versus −2.1 (95% CI −2.89, −1.33) for placebo with therapy; treatment difference −1.20 (95% CI −2.26, −0.14), P = 0.03, with an effect size d = 0.4. Improvements occurred across family, social and work domains. Exploratory outcomes: At 18 weeks, responder rates (≥10-point CAPS-5 reduction) were 86.5% (45/52) in MDMA-AT versus 69.0% (29/42) in placebo with therapy. Loss of diagnosis was observed in 71.2% (37/52) versus 47.6% (20/42), and remission rates were 46.2% (24/52) versus 21.4% (9/42) for MDMA-AT and placebo with therapy, respectively. Number needed to treat (NNT) values reported were: responder = 6, non-responder = 6, loss of diagnosis = 4, remission = 4. Covariate analyses showed similar treatment responses regardless of baseline disease severity, hazardous alcohol or substance use risk, severe adverse childhood experiences or dissociative subtype. Lifetime history of SSRI use interacted significantly with treatment and was associated with greater MDMA-AT efficacy (P = 0.02). Female sex assigned at birth and baseline BDI-II score ≥23 were associated with better outcomes irrespective of treatment assignment. Blinding assessment indicated that most MDMA-AT participants (49/52, 94.2%) believed they had received MDMA, while 75.0% (33/44) of placebo participants believed they had received placebo. Safety: Almost all participants experienced at least one TEAE (102/104, 98.1%). Seven participants experienced severe TEAEs (MDMA-AT 5/53, 9.4%; placebo 2/51, 3.9%); no deaths or serious TEAEs were reported. TEAEs more common with MDMA-AT (incidence >10% and at least double placebo) included muscle tightness, nausea, decreased appetite and hyperhidrosis; these were generally transient and mild or moderate. TEAESIs occurred in 11.3% (6/53) of MDMA-AT and 5.9% (3/51) of placebo participants. Cardiovascular events (palpitations, tachycardia) were more frequent in the MDMA-AT group but were mild; transient, dose-dependent increases in blood pressure and pulse were observed during dosing sessions and did not require clinical intervention. Psychiatric TEAEs (including suicidal ideation, insomnia and anxiety) occurred at similar high frequencies in both groups (MDMA-AT 83.0%; placebo 72.5%); three severe psychiatric events occurred in MDMA-AT and two in placebo, but there were no severe events of suicidal behaviour. Three participants (two MDMA-AT, one placebo) had treatment-emergent active suicidal ideation with some intent (C-SSRS score 4 or 5) on a total of five occasions; one MDMA-AT participant developed active suicidal ideation despite no baseline ideation. No cases of MDMA abuse, misuse, physical dependence or diversion were reported during the study.

Mitchell and colleagues interpret the findings as confirming that MDMA-assisted therapy provides clinically meaningful reductions in PTSD symptom severity and improvements in functioning compared with identical therapy plus placebo over 18 weeks. High responder and loss-of-diagnosis rates in the MDMA-AT arm, together with replication of the earlier MAPP1 results in a more ethnoracially diverse and clinically complex sample, led the investigators to conclude that efficacy is robust across sites and participant subgroups evaluated. The authors note several contextual points: effect sizes in this trial (between-group d = 0.7, within-group d = 1.95) were comparable to MAPP1 and numerically larger than those typically reported for SSRIs, although no head-to-head comparison was performed. They suggest mechanistic plausibility for MDMA-AT—MDMA’s prosocial and anxiolytic effects may enhance psychotherapeutic engagement and processing of traumatic material. Low dropout in the MDMA-AT arm (1.9% versus 15.7% in placebo) is highlighted as consistent across trials and potentially clinically meaningful. Safety findings were consistent with prior studies: transient sympathomimetic effects (increased blood pressure and heart rate), mild-to-moderate cardiac and vascular events in some participants, and psychiatric adverse events including suicidal ideation were observed but not increased beyond baseline or associated with suicidal behaviour. The investigators emphasise that participants at imminent suicide risk, with certain substance use disorders, severe personality disorders or significant cardiovascular disease were excluded, limiting generalisability to those higher-risk populations. They also note that while no evidence of problematic MDMA misuse emerged during the trial, long-term follow-up is needed to assess post-trial risks. Limitations acknowledged by the authors include the trial’s exclusion criteria (which restrict applicability to some clinical populations), the relatively short follow-up period for assessing durability of benefit (assessments extended to 6–8 weeks post final session), and challenges with participant blinding and expectancy—although they argue several observations mitigate expectancy bias. The exploratory finding that lifetime SSRI history, female sex assigned at birth and higher baseline depression scores related to outcomes is noted as hypothesis-generating and requiring further investigation. Finally, the authors suggest additional research comparing MDMA-AT with first-line psychotherapies, evaluating long-term outcomes and assessing implementation needs such as therapist training and safety monitoring if MDMA-AT is approved for clinical use.